Sodium Nitroprusside for Schizophrenia

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Schizophrenia+1 MoreSodium Nitroprusside - Drug
Eligibility
18 - 40
All Sexes
What conditions do you have?
Select

Study Summary

This trial will determine the effectiveness of the drug Sodium Nitroprusside on psychosis symptoms, cognition, and retinal measures in symptomatic Early Course Schizophrenia patients.

Eligible Conditions
  • Schizophrenia
  • Schizoaffective Disorder

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Measured at hour 5

Measured at hour 5
SS-OCTA Retinal Imaging
Measured at week 4
Brief Assessment of Cognition in Schizophrenia (BACS)
Inflammatory Markers
Positive and Negative Syndrome Scale (PANSS)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Side Effects for

Elderly Sodium Nitroprusside
6%Redness at biopsy site
6%Cellulitis
6%Back Pain
This histogram enumerates side effects from a completed 2009 Phase 1 trial (NCT00945256) in the Elderly Sodium Nitroprusside ARM group. Side effects include: Redness at biopsy site with 6%, Cellulitis with 6%, Back Pain with 6%.

Trial Design

2 Treatment Groups

Sodium Nitroprusside Arm
1 of 2
Placebo Arm
1 of 2

Experimental Treatment

Non-Treatment Group

32 Total Participants · 2 Treatment Groups

Primary Treatment: Sodium Nitroprusside · Has Placebo Group · Phase 2

Sodium Nitroprusside Arm
Drug
Experimental Group · 1 Intervention: Sodium Nitroprusside · Intervention Types: Drug
Placebo Arm
Drug
PlaceboComparator Group · 1 Intervention: 5% Dextrose solution · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nitroprusside
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: measured at hour 5

Who is running the clinical trial?

Beth Israel Deaconess Medical CenterLead Sponsor
778 Previous Clinical Trials
844,498 Total Patients Enrolled
19 Trials studying Schizophrenia
1,656 Patients Enrolled for Schizophrenia
Paulo Lizano, MD, PhDPrincipal InvestigatorBeth Israel Deaconess Medical Center

Eligibility Criteria

Age 18 - 40 · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have been taking antipsychotics for at least 2 years.